PARAGON-HF study (Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction)
2020
Abstract
PARAGON-HF study evaluated the treatment with sacubitril/valsartan in patients with heart failure with preserved ejection fraction (HFpEF). Patients were randomised to treatment with sacubitril/valsartan or valsartan alone.
The therapy with sacubitril/valsartan did not lead to significant decrease in risk of hospitalisations for heart failure and decrease in cardiovascular mortality in patients with chronic HfpEF. However, the trend towrds higher clinical efficacy in comparison with valsartan alone is unquestionable.